Immutep will present at the February investor conferences


SYDNEY, AUSTRALIA, Jan. 31, 2022 (GLOBE NEWSWIRE) — Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a biotechnology company developing novel LAG-3-related immunotherapy treatments for cancer and autoimmune diseases, announced today that Immutep CEO Marc Voigt has been invited to participate in the following investor conferences scheduled for February 2022.

11th Annual SVB Leerink Global Healthcare Conference – Virtual
Event dates: February 14 to 18, 2022
One-on-one meetings: Management will be available for one-on-one meetings with institutional investors. Investors interested in scheduling a meeting should contact their SVB Leerink representative.
Event details: www.svbleerink.com/events/

During this virtual conference, Mr. Voigt is scheduled to deliver a company presentation followed by a Q&A session at 3:40 p.m. ET on Friday, February 18. A live webcast of this event, as well as an archived recording, will be available at https://wsw.com/webcast/svbleerink67/immp/2662950.

BIO 2022 CEO & Investor Conference: Hybrid Event
Event dates: February 14 to 17, 2022
One-on-one meetings: Management will be available for one-on-one meetings with institutional investors. Investors interested in scheduling a meeting should contact their BIO CEO representative.
Event details: www.bio.org/events/bio-ceo-investor-conference

About Immutep
Immutep is a globally active biotechnology company that is a leader in the development of LAG-3-related immunotherapeutics for the treatment of cancer and autoimmune diseases. Immutep is committed to leveraging its technology and expertise to bring innovative treatment options to market for patients and maximize shareholder value. Immutep is listed on the Australian Securities Exchange (IMM) and NASDAQ (IMMP) in the United States.

Immutep’s current lead product candidate is eftilagimod alpha (“efti” or “IMP321”), a soluble LAG-3 fusion protein (LAG-3Ig), which is an antigen-presenting cell (APC) activator first in class explored in cancer and infectious diseases. Immutep is also developing a LAG-3 agonist (IMP761) for autoimmune diseases. Other LAG-3 products, including antibodies for modulating the immune response, are being developed by Immutep’s large pharma partners.

Further information can be found on the company’s website www.immutep.com or by contacting:

Australian Investors/Media:
Catherine Strong, Citadel-MAGNUS
+61 (0)406 759 268; [email protected]

American media:
Tim McCarthy, LifeSci Advisors
+1 (212) 915.2564; [email protected]

Previous Nifty PSU Bank Index Climbs 12% in Four Days; SBI nears record high
Next Pierre-Emerick Aubameyang has the last laugh as Arsenal pay the price for a stunning mistake